• The Geek Squad Friday, 23 Mar 2007 | 5:28 PM ET

    When Rodman and Renshaw biotech analyst Mike King told me "Genentech was gonna get its geek on," at its annual analyst meeting today I didn't realize how spot on he might be. Today the company took a deep dive into the science of its drug research and development pipeline...cabbage looper worms and all. I'm not kidding. But the ultimate geek factor came from the company's Chairman and CEO Art Levinson.

  • Amgen's stock fell sharply after the company said it had discontinued a key clinical trial of its drug Vectibix in combination with other drugs as an initial treatment for colon cancer. The report helped boost shares of other drugmakers such as ImClone Systems, which makes a competing drug Erbitux.

  • Here some of Friday's big movers on European stock markets

  • CNBC's Domm: Today's Agenda in the Markets Friday, 23 Mar 2007 | 8:58 AM ET

    Stocks are edging higher ahead of the opening. Existing home sales data at 10 am New York time could influence direction but for now investors face a flurry of Friday morning corporate news headlines.

  • Dendreon Going to the Big Dance Thursday, 22 Mar 2007 | 3:42 PM ET

    A biotech story that I've been following since I started on this beat around four or five years ago is about to go through what's referred to in the biotech world as a major "binary event". In other words, if things go well, the stock could skyrocket. If things go badly, then the stock could tank.

  • Stats, Stats And More Stats¬† For You Wednesday, 21 Mar 2007 | 10:45 AM ET

    We've got some of the latest contest statistics on most active, widely held, etc.  So, without any further introduction, here they are. The numbers are as of Tuesday, March 20, 2007.

  • Pfizer Prevails in Patent Suit Against Teva Tuesday, 20 Mar 2007 | 3:55 PM ET

    The decision bars Teva from launching a competitor drug in the U.S. until December 2015, Pfizer said.

  • The grant, for Cleveland BioLabs' Protectan CBLB502, is designed to fund "development leading to the acquisition" of an radiation countermeasure.

  • Ranbaxy Out of Merck KGaA Generic Hunt; Torrent In? Tuesday, 20 Mar 2007 | 3:29 AM ET

    Ranbaxy Laboratories is no longer in the running to buy the generic drug business of Germany's Merck, India's CNBC TV18 reported Tuesday. Ranbaxy withdrew from the second round of bidding for the business, the television station said.

  • The ACC & DNA; Big Apple to the Big Easy Monday, 19 Mar 2007 | 2:24 PM ET

    We're gearing up for a busy few days on the beat starting Friday. That's when biotech giant Genentech holds its annual analyst meeting in New York City. We'll be there. Last year the company put out new, boosted financial guidance in the middle of the trading day and it moved the stock. CEO Art Levinson told the crowd of analysts he liked to time it that way so they'll stick around for the whole day.

  • Cepheid Meningitis Drug Gets Approval from FDA Friday, 16 Mar 2007 | 1:14 PM ET

    The test, called the Xpert EV test, can detect the condition in 2.5 hours compared with other products that can take as long as a week, the FDA said.

  • U.S. drug maker Bristol-Myers Squibb is moving assets of up to $25 billion from an Irish holding company, it said on Friday, fanning worries in Ireland that it is growing less competitive.

  • Celeb Collins Treading Around "Sub-Million" Thursday, 15 Mar 2007 | 2:41 PM ET
    Stephen Collins

    Stephen Collins continues to dig himself out of sub-million territory gaining $9,284 from Wednesday to end the day at $992,336.24. Here's how the news was handled on "Morning Call." Stephen is the celebrity stock picker for the show's second hour.

  • March Madness is Here: Who Will Profit? Thursday, 15 Mar 2007 | 11:17 AM ET

    Last night I debated John Challenger of Challenger, Gray and Christmas, the firm that each year comes out with that March Madness lost wages study.

  • European Stocks to Watch Thursday, 15 Mar 2007 | 10:34 AM ET

    Here some of Thurday's big movers on European stock markets: Altadis, Imperial Tobacco, Pirelli, Cap Gemini, Swedish Match, Omega Pharma and AstraZeneca.

  • Bayer, one of the world's biggest chemical and pharmaceutical companies, said Thursday its fourth-quarter profit surged nearly seven times because of growth in its health care business.

  • U.S. health regulators have approved GlaxoSmithKline's pill Tykerb for patients with advanced breast cancer after other treatments have failed, a company spokeswoman said on Tuesday.

  • J.P. Garnier, GlaxoSmithKline's chief executive officer, told CNBC's "Squawk Box" Wednesday that he expects to make the company's new drug for advanced breast cancer available to U.S. patients "within a few days."

  • Stars Show "Conservative" Side On First Day Trades Tuesday, 13 Mar 2007 | 10:03 AM ET

    Our celebrity trading has begun--so it's time to see where the stars "stand." Not all have traded yet but for those that have, it seems their approach to investing is more conservative than the majority of our non-celeb leaders--with more stable companies and purchases spread across multiple stocks.

  • Ranbaxy Makes bid for Merck's Generic Drugs Unit Tuesday, 13 Mar 2007 | 8:02 AM ET

    Indian drugmaker Ranbaxy Laboratories said Tuesday it has submitted a bid for the generics unit of Germany's Merck but did not disclose how much it was offering.